Logo image of EQ

EQUILLIUM INC (EQ) Stock Fundamental Analysis

NASDAQ:EQ - Nasdaq - US29446K1060 - Common Stock - Currency: USD

0.796  +0.01 (+0.76%)

After market: 0.8 +0 (+0.5%)

Fundamental Rating

3

Taking everything into account, EQ scores 3 out of 10 in our fundamental rating. EQ was compared to 572 industry peers in the Biotechnology industry. While EQ seems to be doing ok healthwise, there are quite some concerns on its profitability. EQ is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

EQ had negative earnings in the past year.
EQ had a negative operating cash flow in the past year.
In the past 5 years EQ always reported negative net income.
In the past 5 years EQ always reported negative operating cash flow.
EQ Yearly Net Income VS EBIT VS OCF VS FCFEQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

EQ has a better Return On Assets (-13.39%) than 85.51% of its industry peers.
The Return On Equity of EQ (-19.91%) is better than 86.56% of its industry peers.
Industry RankSector Rank
ROA -13.39%
ROE -19.91%
ROIC N/A
ROA(3y)-50.57%
ROA(5y)-46.54%
ROE(3y)-104.42%
ROE(5y)-83.42%
ROIC(3y)N/A
ROIC(5y)N/A
EQ Yearly ROA, ROE, ROICEQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100 -100 -150

1.3 Margins

EQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQ Yearly Profit, Operating, Gross MarginsEQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

EQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EQ has more shares outstanding
Compared to 5 years ago, EQ has more shares outstanding
EQ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EQ Yearly Shares OutstandingEQ Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
EQ Yearly Total Debt VS Total AssetsEQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

EQ has an Altman-Z score of -4.67. This is a bad value and indicates that EQ is not financially healthy and even has some risk of bankruptcy.
EQ has a Altman-Z score (-4.67) which is in line with its industry peers.
There is no outstanding debt for EQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.67
ROIC/WACCN/A
WACC10.76%
EQ Yearly LT Debt VS Equity VS FCFEQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

EQ has a Current Ratio of 3.04. This indicates that EQ is financially healthy and has no problem in meeting its short term obligations.
EQ has a worse Current ratio (3.04) than 63.87% of its industry peers.
EQ has a Quick Ratio of 3.04. This indicates that EQ is financially healthy and has no problem in meeting its short term obligations.
EQ has a Quick ratio of 3.04. This is in the lower half of the industry: EQ underperforms 61.95% of its industry peers.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 3.04
EQ Yearly Current Assets VS Current LiabilitesEQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.67% over the past year.
The Revenue has been growing slightly by 7.70% in the past year.
EPS 1Y (TTM)41.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)7.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%37.1%

3.2 Future

EQ is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.71% yearly.
The Revenue is expected to grow by 20.32% on average over the next years. This is a very strong growth
EPS Next Y-37.33%
EPS Next 2Y-50.71%
EPS Next 3Y-46.89%
EPS Next 5Y-16.71%
Revenue Next Year10.02%
Revenue Next 2Y-41.42%
Revenue Next 3Y-22.42%
Revenue Next 5Y20.32%

3.3 Evolution

EQ Yearly Revenue VS EstimatesEQ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
EQ Yearly EPS VS EstimatesEQ Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EQ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQ Price Earnings VS Forward Price EarningsEQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQ Per share dataEQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

EQ's earnings are expected to decrease with -46.89% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-50.71%
EPS Next 3Y-46.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EQ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EQUILLIUM INC

NASDAQ:EQ (3/7/2025, 8:22:04 PM)

After market: 0.8 +0 (+0.5%)

0.796

+0.01 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners19.88%
Inst Owner Change26.09%
Ins Owners24.39%
Ins Owner Change-1.55%
Market Cap28.20M
Analysts86.67
Price Target4.08 (412.56%)
Short Float %2.99%
Short Ratio0.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)103.24%
Min EPS beat(2)100%
Max EPS beat(2)106.47%
EPS beat(4)4
Avg EPS beat(4)78.31%
Min EPS beat(4)47.34%
Max EPS beat(4)106.47%
EPS beat(8)8
Avg EPS beat(8)106.53%
EPS beat(12)9
Avg EPS beat(12)69.49%
EPS beat(16)12
Avg EPS beat(16)53.06%
Revenue beat(2)1
Avg Revenue beat(2)44.65%
Min Revenue beat(2)-23.33%
Max Revenue beat(2)112.63%
Revenue beat(4)3
Avg Revenue beat(4)45.13%
Min Revenue beat(4)-23.33%
Max Revenue beat(4)112.63%
Revenue beat(8)7
Avg Revenue beat(8)53.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)-14.81%
EPS NQ rev (3m)0%
EPS NY rev (1m)-52.94%
EPS NY rev (3m)-38.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS1.3
BVpS0.65
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.39%
ROE -19.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.57%
ROA(5y)-46.54%
ROE(3y)-104.42%
ROE(5y)-83.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.43%
Cap/Sales 0.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 3.04
Altman-Z -4.67
F-Score5
WACC10.76%
ROIC/WACCN/A
Cap/Depr(3y)119.58%
Cap/Depr(5y)221.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-37.33%
EPS Next 2Y-50.71%
EPS Next 3Y-46.89%
EPS Next 5Y-16.71%
Revenue 1Y (TTM)7.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%37.1%
Revenue Next Year10.02%
Revenue Next 2Y-41.42%
Revenue Next 3Y-22.42%
Revenue Next 5Y20.32%
EBIT growth 1Y27.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.09%
OCF growth 3YN/A
OCF growth 5YN/A